Abbott

Abbott's PCR instrument will help the biopharma companies identify isocitrate dehydrogenase mutations in patients with acute myeloid leukemia.

The court order provided a schedule of actions designed to resolve antitrust issues related to the deal.

The companies appear poised to return to court to settle Alere's claim that Abbott needs to quickly fulfill its obligations under their merger deal.

The firm's confirmation that it is on track with current and Q3 financial report timing may not be enough to appease would-be acquirer Abbott. 

Alere filed a legal complaint in order to push Abbott to obtain the anti-trust approvals needed to complete the acquisition proposed earlier this year.

Although the financial filing sheds increased light on Alere's business, the company is asking for an extension to file its second quarter financial statements.

While Abbott continues to express concerns about the pending acquisition, Alere has remained resolute in its response.   

The firm also reported that it has corrected immaterial errors in previous financial statements.

The company said in December that it had identified a new pegivirus, and is now using that work to redesign an assay that could show how the virus acts in humans.

Abbott's MDx sales were driven by continued strong growth in its infectious disease testing business but were partly offset by the planned scale down of its genetics business.

Pages

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.